Biomarkers & Genetic Testing: How Results Guide Cancer Treatment

Cancer treatment is no longer based only on where a tumor started.
Increasingly, decisions are guided by biomarkers—measurable features of a tumor or a person’s DNA that help predict how a cancer behaves and which treatments are most likely to work.

This guide explains:

what biomarkers and genetic tests are,
the difference between tumor testing and inherited testing,
how results influence treatment,
and what questions patients should ask.

Important: This is educational information, not medical advice. Biomarker results must be interpreted by your oncology team in clinical context.

60-second orientation

Biomarkers are measurable features that give information about a cancer.
Some biomarkers come from the tumor itself; others come from a person’s inherited DNA.
Biomarker testing can help:
select targeted therapies or immunotherapies,
avoid treatments unlikely to help,
estimate prognosis or recurrence risk.
Not all cancers have actionable biomarkers—and that’s normal.

What is a biomarker?

In cancer care, a biomarker is anything measurable that provides information about:

how a cancer behaves,
how aggressive it may be,
or how it might respond to treatment.

Biomarkers can include:

proteins on cancer cells,
genetic mutations or changes,
patterns of gene expression,
features of the tumor’s interaction with the immune system.

The most important distinction: tumor testing vs inherited testing

1) Tumor (somatic) testing

This tests the cancer cells, not the rest of your body.

Looks for genetic changes that developed in the tumor.
Helps identify vulnerabilities that treatments can target.
Results apply to the cancer, not your family.

Examples of what tumor testing can influence:

eligibility for targeted therapies,
likelihood of benefit from immunotherapy,
selection of one drug over another.

2) Inherited (germline) genetic testing

This tests the DNA you were born with.

Looks for inherited mutations passed through families.
Can affect:
cancer risk,
screening recommendations,
treatment decisions in some cancers,
family member testing considerations.

Not everyone needs inherited testing—but it can be important in certain situations.

Ask your team:
“Was my testing done on the tumor, my inherited DNA, or both?”

For a cancer-specific overview of commonly tested biomarkers, see

Biomarkers by cancer type →

Common biomarker categories (plain language)

Receptors and proteins

Some cancers depend on specific proteins to grow. Testing can show whether those proteins are present and relevant.

Genetic mutations or alterations

Tumor DNA can contain changes that:

drive cancer growth,
predict response to certain drugs,
or suggest resistance to others.

Not all mutations are actionable—but identifying them can still inform planning.

Immune-related biomarkers

Some tests estimate how likely a tumor is to respond to immunotherapy by evaluating features of immune interaction or DNA repair.

What biomarker results can (and cannot) tell you

What they can do

Help match treatment to tumor biology
Explain why one therapy is preferred over another
Identify clinical trial options
Avoid ineffective or unnecessary treatments

What they cannot do

Guarantee a treatment will work
Replace clinical judgment
Predict outcomes with certainty

Biomarkers guide decisions—they don’t make them alone.

Why testing timing matters

Biomarker testing may be done:

at diagnosis,
after surgery,
when cancer recurs,
or when considering a new line of therapy.

Results can change over time as cancers evolve under treatment pressure.

Ask:
“Do we need updated testing now, or are prior results still relevant?”

Why results can be confusing for patients

Reports often include:

long gene lists,
technical terms,
variants of unknown significance,
findings with no current treatment relevance.

Seeing a mutation listed does not automatically mean:

there is a drug for it,
it caused your cancer,
or it changes your prognosis.

This is why interpretation—not just results—matters.

How VisitVizor helps make biomarker results usable

Biomarker reports are often scattered across:

pathology reports,
molecular testing PDFs,
clinic notes.

VisitVizor helps by:

organizing test results alongside your scans and labs,
keeping original reports intact,
presenting plain-English summaries to support understanding,
making it easier to track what was tested, when, and why.

The goal is clarity—not diagnosis—so patients can engage meaningfully with their care team.

Questions patients may want to ask

What biomarkers were tested, and why these?
Which results actually change treatment decisions?
Are there treatments available because of these results?
Do any results affect future options or trials?
Do I need inherited genetic testing?
Should testing be repeated later?

Writing these questions down before visits can help focus discussions.

Keep your care organized in VisitVizor

Create a free account to store scans, labs, and visit notes in one secure place.

Create free account Sign in

Educational content stays free — no paywall required.

Deep dive: why “no actionable biomarkers” is still information

Deep dive: why “no actionable biomarkers” is still meaningful information

Hearing that a tumor has “no actionable biomarkers” can feel disappointing or even frightening. Many patients interpret this as: “There’s nothing special about my cancer” or “I’m out of options.”
That reaction is understandable — but it’s usually incorrect.

Here’s what that phrase really means, and why it still provides important guidance for care.

What doctors actually mean by “actionable”

When clinicians say a biomarker is actionable, they mean:

there is a treatment available today (or through a clinical trial),
that treatment is clearly linked to that specific biomarker,
and there is evidence it improves outcomes in this situation.

That is a very high bar.

Many genetic changes can be detected in tumors, but only a subset currently meet all three criteria. So “no actionable biomarkers” usually means no clear drug–marker match right now, not that nothing was found or that nothing matters.

Why most cancers don’t have actionable biomarkers

Despite headlines about “precision medicine,” most cancers are still treated primarily based on:

cancer type,
stage,
tumor grade,
response to prior treatment,
and overall health.

This is not a failure of testing. It reflects biological reality:

Cancer is often driven by complex networks, not a single genetic switch.
Many mutations are common but don’t create a usable drug target.
Some findings matter biologically but don’t change treatment decisions yet.

In other words, the absence of an actionable biomarker is normal, not unusual.

Why this information still helps your care team

Knowing that there are no actionable biomarkers helps doctors:

avoid pursuing ineffective targeted therapies,
choose proven standard treatments with confidence,
plan therapy sequencing more clearly,
set realistic expectations about what testing can and can’t do.

It narrows the decision space — and clarity matters in cancer care.

“No actionable biomarkers” does NOT mean

It does not mean:

there are no effective treatments,
chemotherapy is your only option forever,
immunotherapy is impossible,
clinical trials are off the table,
or that your cancer is “worse” than others.

Many cancers without actionable biomarkers respond well to standard treatments, sometimes for long periods. How a cancer responds to therapy often matters more than molecular findings alone.

Why standard treatments are still powerful

Standard therapies are “standard” because they:

have helped large numbers of people,
across real-world populations,
with predictable benefits and known risks.

In many situations, outcomes with standard therapy are better established than outcomes with newer targeted drugs that are still early in use.

Precision medicine does not replace standard care — it builds on it when appropriate.

Biomarkers can become relevant later

Biomarker testing is not always a one-time decision point.

Over time:

cancers can evolve,
new drugs can be approved,
clinical trials can open,
and previously “non-actionable” findings can become relevant.

This is why teams sometimes revisit testing later, especially at recurrence or progression.

A useful question to ask is:
“Is there any reason to repeat testing in the future, or are these results likely to stay relevant?”

The emotional impact is real — and often overlooked

For many patients, biomarker testing creates hope for something “special” or “targeted,” followed by disappointment when results don’t unlock a clear option.

That reaction is human.

But good cancer care is not about finding something rare or clever — it’s about choosing the right next step, at the right time, for the right reasons.

Understanding this can reduce anxiety, self-blame, and the feeling of “missing out.”

Because biomarker relevance varies widely by cancer type, results are best understood in context.
You can see common patterns summarized in
Biomarkers by cancer type →

How VisitVizor helps in this situation

When biomarker results don’t change treatment, patients still want to understand:

what was tested,
why it was tested,
and whether it might matter later.

VisitVizor helps by:

keeping biomarker reports organized alongside your timeline,
summarizing what does and does not influence decisions,
preserving results so they can be revisited if circumstances change.

This turns “no actionable biomarkers” from a dead end into documented context.

A healthier way to frame the result

Instead of thinking:

“There’s nothing actionable.”

A more accurate framing is:

“Right now, the best treatment decisions are guided by clinical factors and proven therapies.”

That’s not a lack of options.
That’s informed care.

Practical: what to keep copies of

pathology report
molecular / biomarker testing report
inherited genetic testing summary (if done)
treatment summary showing which decisions used these results

Having these together makes second opinions and future decisions easier.

Sources and review

This guide summarizes common principles of biomarker-driven cancer care and genetic testing interpretation.

Last reviewed: 2026-02-01